RU2015135806A - Соединения - Google Patents

Соединения Download PDF

Info

Publication number
RU2015135806A
RU2015135806A RU2015135806A RU2015135806A RU2015135806A RU 2015135806 A RU2015135806 A RU 2015135806A RU 2015135806 A RU2015135806 A RU 2015135806A RU 2015135806 A RU2015135806 A RU 2015135806A RU 2015135806 A RU2015135806 A RU 2015135806A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
formula
group
Prior art date
Application number
RU2015135806A
Other languages
English (en)
Russian (ru)
Inventor
Цзехун Вань
Сяомин Чжан
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of RU2015135806A publication Critical patent/RU2015135806A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2015135806A 2013-01-25 2014-01-23 Соединения RU2015135806A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/070970 2013-01-25
CN2013070970 2013-01-25
PCT/CN2014/071205 WO2014114248A1 (en) 2013-01-25 2014-01-23 Compounds

Publications (1)

Publication Number Publication Date
RU2015135806A true RU2015135806A (ru) 2017-03-03

Family

ID=51226938

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015135806A RU2015135806A (ru) 2013-01-25 2014-01-23 Соединения

Country Status (10)

Country Link
US (1) US9296755B2 (https=)
EP (1) EP2948457A4 (https=)
JP (1) JP2016508995A (https=)
KR (1) KR20150111356A (https=)
CN (1) CN105008365B (https=)
AU (1) AU2014210259B2 (https=)
BR (1) BR112015017768A2 (https=)
CA (1) CA2899124A1 (https=)
RU (1) RU2015135806A (https=)
WO (1) WO2014114248A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2820903C1 (ru) * 2020-06-30 2024-06-11 Неуско Биотек Лимитед Получение и применение трициклического пиримидинонового соединения и его композиции

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CN112778331B (zh) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
TWI896037B (zh) 2023-07-17 2025-09-01 大陸商上海樞境生物科技有限公司 雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
CN1175246A (zh) 1994-12-22 1998-03-04 史密丝克莱恩比彻姆有限公司 用于治疗动脉粥样硬化的取代的氮杂环丁-2-酮
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
JP2002515852A (ja) 1995-07-01 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン誘導体
EP0859834A2 (en) 1995-09-29 1998-08-26 Smithkline Beecham Plc A paf-acetylhydrolase and use in therapy
WO1997021675A1 (en) 1995-12-08 1997-06-19 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
WO1997021676A1 (en) 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
NZ332476A (en) 1996-04-26 2000-06-23 Smithkline Beecham Plc substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivatives
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1999024420A1 (en) 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
US6559155B1 (en) 1998-08-21 2003-05-06 Smithkline Beecham P.L.C. Pyrimidinone derivatives for the treatment of atherosclerosis
HUP0201122A3 (en) 1999-05-01 2003-11-28 Smithkline Beecham Plc Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
EP1686119B1 (en) 2000-02-16 2009-07-29 Smithkline Beecham Plc Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1558606A4 (en) 2002-10-02 2008-05-07 Bristol Myers Squibb Co DIAMINOALKYL CONTAINING LACTAM, BETA AMINO ACIDS, ALPHA AMINO ACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
MXPA05003607A (es) 2002-10-04 2005-11-17 Prana Biotechnology Ltd Compuestos neurologicamente activos.
CA2530816A1 (en) 2003-07-02 2005-01-13 Bayer Healthcare Ag Amide-substituted 1,2,4-triazin-5(2h)-ones for the treatment of chronic inflammatory diseases
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
WO2008048867A2 (en) * 2006-10-13 2008-04-24 Glaxo Group Limited Bicyclic heteroaromatic compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US20080279846A1 (en) * 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
EP2521724B1 (en) 2009-12-11 2016-11-23 Nono Inc. Agents and methods for treating ischemic and other diseases
PE20140421A1 (es) * 2010-12-06 2014-04-26 Glaxo Group Ltd COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
AR087309A1 (es) * 2011-07-27 2014-03-12 Glaxo Group Ltd Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2820903C1 (ru) * 2020-06-30 2024-06-11 Неуско Биотек Лимитед Получение и применение трициклического пиримидинонового соединения и его композиции

Also Published As

Publication number Publication date
EP2948457A4 (en) 2016-09-07
US20150322075A1 (en) 2015-11-12
AU2014210259A1 (en) 2015-07-30
AU2014210259B2 (en) 2016-11-03
JP2016508995A (ja) 2016-03-24
KR20150111356A (ko) 2015-10-05
US9296755B2 (en) 2016-03-29
CA2899124A1 (en) 2014-07-31
BR112015017768A2 (pt) 2017-07-11
WO2014114248A1 (en) 2014-07-31
EP2948457A1 (en) 2015-12-02
CN105008365A (zh) 2015-10-28
CN105008365B (zh) 2017-03-15

Similar Documents

Publication Publication Date Title
JP2016506935A5 (https=)
JP2014511892A5 (https=)
RU2016134751A (ru) Соединения
JP2014511891A5 (https=)
JP2019517487A5 (https=)
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
JP2013537203A5 (https=)
JP2016514159A5 (https=)
EA201790088A1 (ru) Ингибиторы syk
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2016515561A5 (https=)
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
CY1118340T1 (el) Αναστολεις κινασης
JP2015537020A5 (https=)
MD4551B1 (ro) Derivaţi pe bază de tetrahidroizochinoline şi N-(fenilfosfat)amide, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
JP2017504635A5 (https=)
JOP20130256B1 (ar) مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
JP2015504081A5 (https=)
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
RU2016131189A (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
RU2019114940A (ru) Лечение катаплексии
JP2016522266A5 (https=)
EA202090977A1 (ru) Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild)
JP2013532668A5 (https=)
RU2015135824A (ru) Бициклические соединения пиримидона в качестве ингибиторов lp-pla2

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180329